What one share of Compass Therapeutics holds
We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth.
Compass Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.40 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.31 |
| Cash and investments | $1.00 |
| Book value | $0.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.01 | — | — | — | −$0.01 |
| 2019 | — | −$5.19 | $0.07 | −$4.81 | — | $1.60 |
| 2020 | — | −$0.01 | — | — | — | −$0.02 |
| 2020 | — | −$0.96 | $0.00 | −$0.87 | — | $0.78 |
| 2021 | — | −$1.31 | $0.02 | −$0.34 | — | $1.39 |
| 2022 | — | −$0.37 | $0.00 | −$0.33 | — | $1.44 |
| 2023 | $0.00 | −$0.33 | $0.00 | −$0.32 | — | $1.16 |
| 2024 | $0.01 | −$0.36 | $0.00 | −$0.33 | — | $0.91 |
| 2025 | $0.00 | −$0.42 | $0.00 | −$0.31 | — | $1.10 |
Common questions about Compass Therapeutics
How much does one share of Compass Therapeutics earn?
Over the last 12 months, Compass Therapeutics lost $0.40 for each share.
Does Compass Therapeutics pay a dividend?
Compass Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Compass Therapeutics’s book value per share?
Compass Therapeutics’s book value is $0.92 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Compass Therapeutics have?
Each share of Compass Therapeutics has $1.00 of cash and investments, as of June 30, 2026.
What is Compass Therapeutics’s free cash flow per share?
−$0.31 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Compass Therapeutics bought back shares?
Compass Therapeutics’s share count rose about 3054% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.